Skip to main content
. Author manuscript; available in PMC: 2021 May 3.
Published in final edited form as: Biomed Pharmacother. 2020 Dec 8;133:111058. doi: 10.1016/j.biopha.2020.111058

Table 2.

The IC50s of the FDA-approved drugs and TMZ on GSC viabilities.

Drugs 0827 GSC IC50 (μM, 95% CI) 0827 d-GC IC50 (μM, 95% CI) 0923 GSC IC50 μM (95% CI) 0923 d-GC IC50 μM (95% CI)
Pyrvinium pamoate 0.1 (0.1 – 0.2) 0.5 (0.3 – 0.9) 0.9 (0.7 – 1.2) 5.3 (3.5 – 7.9)
Trifluoperazine 4.7 (3.4 – 6.5) >100 9.1 (6.8 – 12.5) 35.7 (22.8 – 66.5)
Mitoxantrone 1.8 (1.4 – 2.4) 10.2 (8.5–12.2) 2.6 (2.1 – 3.2) 3.0 (1.9 – 4.8)
Temozolomide >100 >100 >100 >100